EPISODE · May 30, 2026 · 6 MIN
Why Pharma Patents Expire and How Pfizer Is Handling the Cliff
from The Investing Podcast with Fexingo: Stocks, Bonds, and Building a Long-Term Portfolio · host Fexingo
Episode 20 of The Investing Podcast with Fexingo examines the 'patent cliff' that hits major drugmakers when blockbuster exclusivity ends. Lucas and Luna use Pfizer as a case study, noting that the company faces $17 billion in revenue at risk by 2030 as patents on Eliquis, Xtandi, and other key drugs expire. They break down Pfizer's strategy: cutting costs, leaning on its COVID vaccine franchise (Comirnaty), and pursuing targeted acquisitions. The hosts also touch on the broader market backdrop — the S&P 500 at 7,580 and energy stocks like ExxonMobil down over 6 percent in a week. A specific look at how pharma companies navigate the cliff, with numbers and timelines listeners can use. #Pfizer #PatentCliff #PharmaStocks #Eliquis #Comirnaty #DrugPatents #Investing #HealthcareStocks #DividendStocks #Biotech #MergersAndAcquisitions #CostCutting #RevenueAtRisk #S&P500 #EnergyStocks #Finance #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo
What this episode covers
Episode 20 of The Investing Podcast with Fexingo examines the 'patent cliff' that hits major drugmakers when blockbuster exclusivity ends. Lucas and Luna use Pfizer as a case study, noting that the company faces $17 billion in revenue at risk by 2030 as patents on Eliquis, Xtandi, and other key drugs expire. They break down Pfizer's strategy: cutting costs, leaning on its COVID vaccine franchise (Comirnaty), and pursuing targeted acquisitions. The hosts also touch on the broader market backdrop — the S&P 500 at 7,580 and energy stocks like ExxonMobil down over 6 percent in a week. A specific look at how pharma companies navigate the cliff, with numbers and timelines listeners can use. #Pfizer #PatentCliff #PharmaStocks #Eliquis #Comirnaty #DrugPatents #Investing #HealthcareStocks #DividendStocks #Biotech #MergersAndAcquisitions #CostCutting #RevenueAtRisk #S&P500 #EnergyStocks #Finance #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo
NOW PLAYING
Why Pharma Patents Expire and How Pfizer Is Handling the Cliff
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.